Prelude Therapeutics Inc (PRLD) stock
PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026Score 7/3067% above fair value
$3.45−0.07 (-1.99%)
Close on Nov 13, 2026Market cap $275.32MP/E –Yield –
Prelude Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Prelude Therapeutics's total assets was $189.36M at Jun 30, 2026. For fiscal 2025 it was $141.32M, down 19.5% from the year before. The highest annual figure on record is $305.10M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $141.32M | -19.5% |
| FY2024 | Dec 31, 2024 | $175.52M | -36.8% |
| FY2023 | Dec 31, 2023 | $277.67M | +25.9% |
| FY2022 | Dec 31, 2022 | $220.50M | -27.7% |
| FY2021 | Dec 31, 2021 | $305.10M | +36.5% |
| FY2020 | Dec 31, 2020 | $223.59M | +922.3% |
| FY2019 | Dec 31, 2019 | $21.87M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $189.36M | +64.8% |
| Q1 FY2026 | Mar 31, 2026 | $119.64M | -15.3% |
| Q4 FY2025 | Dec 31, 2025 | $141.32M | -19.5% |
| Q3 FY2025 | Sep 30, 2025 | $94.76M | -52.0% |
| Q2 FY2025 | Jun 30, 2025 | $114.92M | -48.8% |
| Q1 FY2025 | Mar 31, 2025 | $141.26M | -42.8% |
| Q4 FY2024 | Dec 31, 2024 | $175.52M | -36.8% |
| Q3 FY2024 | Sep 30, 2024 | $197.22M | -23.7% |
| Q2 FY2024 | Jun 30, 2024 | $224.29M | -20.1% |
| Q1 FY2024 | Mar 31, 2024 | $247.11M | +24.6% |
| Q4 FY2023 | Dec 31, 2023 | $277.67M | +25.9% |
| Q3 FY2023 | Sep 30, 2023 | $258.51M | +6.7% |
| Q2 FY2023 | Jun 30, 2023 | $280.61M | +8.3% |
| Q1 FY2023 | Mar 31, 2023 | $198.32M | -29.3% |
| Q4 FY2022 | Dec 31, 2022 | $220.50M | -27.7% |
| Q3 FY2022 | Sep 30, 2022 | $242.33M | -26.8% |
| Q2 FY2022 | Jun 30, 2022 | $259.06M | -25.9% |
| Q1 FY2022 | Mar 31, 2022 | $280.67M | -24.1% |
| Q4 FY2021 | Dec 31, 2021 | $305.10M | +36.5% |
| Q3 FY2021 | Sep 30, 2021 | $331.22M | +38.2% |
| Q2 FY2021 | Jun 30, 2021 | $349.58M | +1498.4% |
| Q1 FY2021 | Mar 31, 2021 | $369.83M | – |
| Q4 FY2020 | Dec 31, 2020 | $223.59M | – |
| Q3 FY2020 | Sep 30, 2020 | $239.68M | – |
| Q4 FY2019 | Dec 31, 2019 | $21.87M | – |
See a number that looks wrong?